Table 3 The detailed adverse events and recurrent episodes in the two groups
EUS-first (n = 44) | ERCP-first (n = 60) | P value | |
|---|---|---|---|
All events (%) | 3 (6.8) | 13 (21.7) | 0.04 |
Pancreatitis | |||
Mild to moderate | 1 (2.3) | 1 (1.7) | |
Severe | 0 | 0 | |
Bleeding | |||
Endoscopic treatment | 1 (2.3) | 8 (13.3) | |
TAE* or surgical treatment | 0 | 0 | |
Ascending cholangitis | |||
Fever or sepsis | 0 | 3 (5.0) | |
Septic shock | 1 (2.3) | 0 | |
Others | 0 | 1† (1.7) | |
NNT‡ for avoiding complications | 6.71 |
Recurrent episode within 3 months | ||||
|---|---|---|---|---|
EUS (n = 27) | EUS + ERCP (n = 17) | ERCP (n = 60) | P value | |
Total recurrence | 2 | 4 | 9 | 0.12 |
Biliary colic | 1 | 2 | 1 | |
Cholecystitis | 1 | 0 | 6 | |
Recurrent CBD stone | 0 | 2 | 2 | |
Biliary pancreatitis | 0 | 0 | 0 | |